Galetin A - Search Results

1

Progress towards prediction of human pharmacokinetic parameters from in vitro technologies.

Houston JB, Galetin A. Houston JB, et al. Among authors: galetin a. Drug Metab Rev. 2003 Nov;35(4):393-415. doi: 10.1081/dmr-120026870. Drug Metab Rev. 2003. PMID: 14705868 Review.

2

Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach.

Galetin A, Clarke SE, Houston JB. Galetin A, et al. Drug Metab Dispos. 2002 Dec;30(12):1512-22. doi: 10.1124/dmd.30.12.1512. Drug Metab Dispos. 2002. PMID: 12433827

3

Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.

Galetin A, Clarke SE, Houston JB. Galetin A, et al. Drug Metab Dispos. 2003 Sep;31(9):1108-16. doi: 10.1124/dmd.31.9.1108. Drug Metab Dispos. 2003. PMID: 12920166

4

Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.

Galetin A, Brown C, Hallifax D, Ito K, Houston JB. Galetin A, et al. Drug Metab Dispos. 2004 Dec;32(12):1411-20. doi: 10.1124/dmd.104.000844. Epub 2004 Sep 1. Drug Metab Dispos. 2004. PMID: 15342470

5

Modelling atypical CYP3A4 kinetics: principles and pragmatism.

Houston JB, Galetin A. Houston JB, et al. Among authors: galetin a. Arch Biochem Biophys. 2005 Jan 15;433(2):351-60. doi: 10.1016/j.abb.2004.09.010. Arch Biochem Biophys. 2005. PMID: 15581591 Review.

6

CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.

Galetin A, Ito K, Hallifax D, Houston JB. Galetin A, et al. J Pharmacol Exp Ther. 2005 Jul;314(1):180-90. doi: 10.1124/jpet.104.082826. Epub 2005 Mar 22. J Pharmacol Exp Ther. 2005. PMID: 15784650

7

Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans.

Rawden HC, Carlile DJ, Tindall A, Hallifax D, Galetin A, Ito K, Houston JB. Rawden HC, et al. Among authors: galetin a. Xenobiotica. 2005 Jun;35(6):603-25. doi: 10.1080/00498250500162870. Xenobiotica. 2005. PMID: 16192111

8

Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition.

Galetin A, Burt H, Gibbons L, Houston JB. Galetin A, et al. Drug Metab Dispos. 2006 Jan;34(1):166-75. doi: 10.1124/dmd.105.006874. Epub 2005 Oct 12. Drug Metab Dispos. 2006. PMID: 16221752

9

Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.

Brown HS, Ito K, Galetin A, Houston JB. Brown HS, et al. Among authors: galetin a. Br J Clin Pharmacol. 2005 Nov;60(5):508-18. doi: 10.1111/j.1365-2125.2005.02483.x. Br J Clin Pharmacol. 2005. PMID: 16236041 Free PMC article.

10

Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.

Galetin A, Houston JB. Galetin A, et al. J Pharmacol Exp Ther. 2006 Sep;318(3):1220-9. doi: 10.1124/jpet.106.106013. Epub 2006 Jun 8. J Pharmacol Exp Ther. 2006. PMID: 16763093

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results